Onabotulinum Toxin A (BoNT‐A) for Drooling in Children: A Systematic Review and Meta‐Analysis
The Laryngoscope · 2024
DOI: 10.1002/lary.31277 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Laryngoscope, 2024. Verfasst von Haresh Oad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Sialorrhea, Botulinum Toxins, Type A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Sialorrhea, also known as drooling, hypersalivation, or ptyalism, has a significant impact on the medical and psychosocial well‐being of children. Onabotulinum toxin A (BoNT‐A) is the most commonly used botulinum toxin worldwide for the treatment of sialorrhea in children.
Objectives
To conduct a comprehensive systematic review and meta‐analysis to assess the clinical efficacy and potential adverse effects of BoNT‐A as a treatment for drooling in children.
Methods
Cochrane, Embase, and Medline databases were systematically searched (up to May 2023). Out of 535 identified publications, 20 were found eligible for inclusion. A systematic review and meta‐analysis were performed to determine the efficacy of BoNT‐A treatment in children in reducing the frequency and severity of drooling.
Results
Out of the 20 studies included, a meta‐analysis was conducted on the complete dataset of eight studies involving 131 patients. BoNT‐A was found to significantly decrease the severity of drooling in patients with sialorrhea (standardized mean difference [SMD], −2.07; 95% confidence interval [CI], −2.91 to −1.23; p < 0.0001) when compared with the conditions before injections using random‐effects models. Six studies out of 20 reported dysphagia as an adverse effect after injection. Other side effects included thickness of saliva and pain at the site of injection.
Conclusion
BoNT‐A is a clinically effective therapy that improves drooling severity in children with sialorrhea. Although there were some adverse side effects reported, they were transient and not severe. Future studies are needed to further evaluate the best techniques and to identify the ideal dosages required to achieve the optimal outcomes. Laryngoscope , 134:3012–3017, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Sabrina D da Silva, Sam J Daniel
Zitieren
APA
Oad, H., Maltezeanu, A., da Silva, S. D., & Daniel, S. J. (2024). Onabotulinum Toxin A (BoNT‐A) for Drooling in Children: A Systematic Review and Meta‐Analysis. The Laryngoscope. https://doi.org/10.1002/lary.31277
Vancouver
Oad H, Maltezeanu A, da Silva SD, Daniel SJ. Onabotulinum Toxin A (BoNT‐A) for Drooling in Children: A Systematic Review and Meta‐Analysis. The Laryngoscope. 2024. doi:10.1002/lary.31277
BibTeX
@article{Oad2024,
author = {Oad, Haresh and Maltezeanu, Alix and da Silva, Sabrina D and Daniel, Sam J},
title = {Onabotulinum Toxin A (BoNT‐A) for Drooling in Children: A Systematic Review and Meta‐Analysis},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.31277}
}
EUVIMED